ENTITY
Innovent Biologics Inc

Innovent Biologics Inc (1801 HK)

357
Analysis
Health CareChina
Innovent Biologics, Inc. operates as a biopharmaceutical company. The Company develops, manufactures, and distributes monoclonal antibody drug candidates for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and other diseases. Innovent Biologics serves customers in China.
more
Refresh
23 Apr 2020 12:35

Akesobio: Trading Debut, Valuation Scenario Analysis

Akeso Biopharma Inc (9926 HK) is a clinical-stage biopharmaceutical company with aims to address global unmet medical needs in oncology, immunology...

Logo
461 Views
Share
14 Apr 2020 14:04

Akesobio IPO: Valuation Insights

Akeso Biopharma Inc (9926 HK) is a clinical-stage biopharmaceutical company with aims to address global unmet medical needs in oncology, immunology...

Logo
469 Views
Share
08 Apr 2020 19:50

Akesobio IPO Initiation: The Tough Get Going

Akeso Biopharma Inc (1495016D CH) is a clinical-stage biopharmaceutical company with aims to address global unmet medical needs in oncology,...

Logo
460 Views
Share
bullishByteDance
16 Feb 2020 09:58

ECM Weekly (16 Feb 2020) - ThaiBev Brewery, ByteDance, China Bright Culture, Equitas SFB, LIC

Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs. ECM...

Share
12 Feb 2020 18:35

Innovent Biologics Placement: Positive Newsflow Bodes Well for Capital Raising

Innovent Biologics is raising USD 270 million to fund its clinical trial and commercialization of Tyvyt (PD-1). We have covered the company's...

Logo
418 Views
Share
x